SAN FRANCISCO — Malignant pheochromocytomas appeared to feature a variety of genomic alterations, some of which, including RET, NF1 and FGFR1, may be potential targets for therapy in the metastatic setting, according to results of a comprehensive genomic profiling study presented at Genitourinary Cancers Symposium.

“Malignant pheochromocytomas are a rare form of endocrine malignancy that can occur in familial and sporadic clinical settings,” Gennady Bratslavsky, MD, professor and chair of urology at Upstate Medical Center and urologic surgeon and oncologist at Upstate Cancer Center, said during his presentation. “We performed comprehensive genomic profiling to characterize genomic alterations in malignant pheochromocytoma and to enable the search for potential therapy targets.”